BACKGROUND: Pancreatic cancer is recognized as one of the most fatal tumors due to its aggressiveness and resistance to therapy. Statins were previously shown to inhibit the proliferation of cancer cells via various signaling pathways. In healthy tissues, statins activate the heme oxygenase pathway, nevertheless the role of heme oxygenase in pancreatic cancer is still controversial. The aim of this study was to evaluate, whether anti-proliferative effects of statins in pancreatic cancer cells are mediated via the heme oxygenase pathway. METHODS: In vitro effects of various statins and hemin, a heme oxygenase inducer, on cell proliferation were evaluated in PA-TU-8902, MiaPaCa-2 and BxPC-3 human pancreatic cancer cell lines. The effect of statins on heme oxygenase activity was assessed and heme oxygenase-silenced cells were used for pancreatic cancer cell proliferation studies. Cell death rate and reactive oxygen species production were measured in PA-TU-8902 cells, followed by evaluation of the effect of cerivastatin on GFP-K-Ras trafficking and expression of markers of invasiveness, osteopontin (SPP1) and SOX2. RESULTS: While simvastatin and cerivastatin displayed major anti-proliferative properties in all cell lines tested, pravastatin did not affect the cell growth at all. Strong anti-proliferative effect was observed also for hemin. Co-treatment of cerivastatin and hemin increased anti-proliferative potential of these agents, via increased production of reactive oxygen species and cell death compared to individual treatment. Heme oxygenase silencing did not prevent pancreatic cancer cells from the tumor-suppressive effect of cerivastatin or hemin. Cerivastatin, but not pravastatin, protected Ras protein from trafficking to the cell membrane and significantly reduced expressions of SPP1 (p < 0.05) and SOX2 (p < 0.01). CONCLUSIONS: Anti-proliferative effects of statins and hemin on human pancreatic cancer cell lines do not seem to be related to the heme oxygenase pathway. While hemin triggers reactive oxygen species-induced cell death, cerivastatin targets Ras protein trafficking and affects markers of invasiveness.

4th Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Katerinska 32 Prague 2 120 00 Czech Republic

Department of Biochemistry and Microbiology University of Chemistry and Technology Technicka 1905 5 Prague 6 160 00 Czech Republic

Department of Surgery University Hospital Kralovske Vinohrady and Charles University Prague Srobarova 50 Prague 10 100 34 Czech Republic

Institute of Biotechnology Czech Academy of Sciences Videnska 1083 Prague 4 142 20 Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University Prague Katerinska 32 Prague 2 120 00 Czech Republic

School of Medical Science Griffith University Parklands Avenue 4222 Southport QLD Australia

Zobrazit více v PubMed

Vitek L, Lenicek M. Cytoprotective and antiproliferative effects of HMG-CoA reductase inhibitors. Curr Enz Inhib. 2006;2:261–80. doi: 10.2174/157340806777934775. DOI

Hawk MA, Cesen KT, Siglin JC, Stoner GD, Ruch RJ. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett. 1996;109(1–2):217–22. doi: 10.1016/S0304-3835(96)04465-5. PubMed DOI

Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999;5(8):2223–9. PubMed

Gbelcova H, Lenicek M, Zelenka J, Knejzlik Z, Dvorakova G, Zadinova M, et al. Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer. 2008;122(6):1214–21. doi: 10.1002/ijc.23242. PubMed DOI

Sumi S, Beauchamp RD, Townsend CM, Uchida T, Murakami M, Rajaraman S, et al. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology. 1992;103(3):982–9. PubMed

Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res. 2001;61(12):4885–91. PubMed

Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, et al. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology. 2002;122(2):308–17. doi: 10.1053/gast.2002.31093. PubMed DOI

Elson CE, Peffley DM, Hentosh P, Mo H. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc Soc Exp Biol Med. 1999;221(4):294–311. doi: 10.3181/00379727-221-44413. PubMed DOI

Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell. 2005;7(4):297–300. doi: 10.1016/j.ccr.2005.04.005. PubMed DOI

Pronk GJ, Bos JL. The role of p21ras in receptor tyrosine kinase signalling. Biochim Biophys Acta. 1994;1198(2–3):131–47. PubMed

Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279(5350):509–14. doi: 10.1126/science.279.5350.509. PubMed DOI

Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3’-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2002;1(12):989–97. PubMed

Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53(4):549–54. doi: 10.1016/0092-8674(88)90571-5. PubMed DOI

Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006;86(2):583–650. doi: 10.1152/physrev.00011.2005. PubMed DOI

Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med. 1996;2:87–90. doi: 10.1038/nm0196-87. PubMed DOI

Lin Q, Weis S, Yang G, Weng YH, Helston R, Rish K, et al. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J Biol Chem. 2007;282(28):20621–33. doi: 10.1074/jbc.M607954200. PubMed DOI

Liu H, Nowak R, Chao W, Bloch KD. Nerve growth factor induces anti-apoptotic heme oxygenase-1 in rat pheochromocytoma PC12 cells. J Neurochem. 2003;86(6):1553–63. doi: 10.1046/j.1471-4159.2003.01978.x. PubMed DOI

Wegiel B, Nemeth Z, Correa-Costa M, Bulmer AC, Otterbein LE. Heme oxygenase-1: a metabolic nike. Antioxid Redox Signal. 2014;20(11):1709–22. doi: 10.1089/ars.2013.5667. PubMed DOI PMC

Was H, Dulak J, Jozkowicz A. Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets. 2010;11(12):1551–70. doi: 10.2174/1389450111009011551. PubMed DOI

Grosser N, Erdmann K, Hemmerle A, Berndt G, Hinkelmann U, Smith G, et al. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem Biophys Res Commun. 2004;325(3):871–6. doi: 10.1016/j.bbrc.2004.10.123. PubMed DOI

Grosser N, Hemmerle A, Berndt G, Erdmann K, Hinkelmann U, Schurger S, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med. 2004;37(12):2064–71. doi: 10.1016/j.freeradbiomed.2004.09.009. PubMed DOI

Lee TS, Chang CC, Zhu Y, Shyy JYJ. Simvastatin induces heme oxygenase-1 - A novel mechanism of vessel protection. Circulation. 2004;110(10):1296–302. doi: 10.1161/01.CIR.0000140694.67251.9C. PubMed DOI

Hsu M, Muchova L, Morioka I, Wong RJ, Schroder H, Stevenson DK. Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem Biophys Res Commun. 2006;343(3):738–44. doi: 10.1016/j.bbrc.2006.03.036. PubMed DOI

Muchova L, Wong RJ, Hsu M, Morioka I, Vitek L, Zelenka J, et al. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol. 2007;85(8):800–10. doi: 10.1139/Y07-077. PubMed DOI

Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Kunzli B, et al. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res. 2005;11(10):3790–8. doi: 10.1158/1078-0432.CCR-04-2159. PubMed DOI

Muchova L, Vanova K, Suk J, Micuda S, Dolezelova E, Fuksa L, et al. Protective effect of heme oxygenase induction in ethinylestradiol-induced cholestasis. J Cell Mol Med. 2015;19(5):924–33. doi: 10.1111/jcmm.12401. PubMed DOI PMC

Vreman HJ, Stevenson DK. Heme oxygenase activity as measured by carbon monoxide production. Anal Biochem. 1988;168(1):31–8. doi: 10.1016/0003-2697(88)90006-1. PubMed DOI

Kita K, Saito S, Morioka CY, Watanabe A. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int J Cancer. 1999;80(4):553–8. doi: 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6. PubMed DOI

Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, et al. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. Br J Cancer. 2014;111(9):1788–801. doi: 10.1038/bjc.2014.475. PubMed DOI PMC

Hinkelmann U, Grosser N, Erdmann K, Schroder H, Immenschuh S. Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci. 2010;41(1):118–24. doi: 10.1016/j.ejps.2010.05.021. PubMed DOI

Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, et al. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol. 2015;21(16):4788–801. doi: 10.3748/wjg.v21.i16.4788. PubMed DOI PMC

Khurana V, Sheth A, Caldito G, Barkin JS. Statins reduce the risk of pancreatic cancer in humans: a case–control study of half a million veterans. Pancreas. 2007;34(2):260–5. doi: 10.1097/MPA.0b013e318030e963. PubMed DOI

Walker EJ, Ko AH, Holly EA, Bracci PM. Statin use and risk of pancreatic cancer: results from a large, clinic-based case–control study. Cancer. 2015;121(8):1287–94. doi: 10.1002/cncr.29256. PubMed DOI PMC

Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, et al. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis. 2003;6(1):15–24. doi: 10.1023/A:1025803600840. PubMed DOI

Glei M, Klenow S, Sauer J, Wegewitz U, Richter K, Pool-Zobel BL. Hemoglobin and hemin induce DNA damage in human colon tumor cells HT29 clone 19A and in primary human colonocytes. Mutat Res. 2006;594(1–2):162–71. doi: 10.1016/j.mrfmmm.2005.08.006. PubMed DOI

Tsuji A, Wang J, Stenzel KH, Novogrodsky A. Immune stimulatory and anti-tumour properties of haemin. Clin Exp Immunol. 1993;93(3):308–12. doi: 10.1111/j.1365-2249.1993.tb08177.x. PubMed DOI PMC

Vitek L. Statins and pancreatic cancer: are all statins the same? Am J Gastroenterol. 2009;104(2):525. doi: 10.1038/ajg.2008.103. PubMed DOI

Qi XF, Zheng L, Lee KJ, Kim DH, Kim CS, Cai DQ, et al. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis. 2013;4 doi: 10.1038/cddis.2013.44. PubMed DOI PMC

Collins MA, Pasca di Magliano M. Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol. 2013;4:407. PubMed PMC

Zhivkova-Galunska M, Adwan H, Eyol E, Kleeff J, Kolb A, Bergmann F, et al. Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines. Canc Biol Ther. 2010;10(1):54–64. doi: 10.4161/cbt.10.1.12161. PubMed DOI

Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas. 2006;32(2):164–70. doi: 10.1097/01.mpa.0000202947.80117.a0. PubMed DOI

Li JJ, Li HY, Gu F. Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta-analysis. Genet Test Mol Biomarkers. 2014;18(8):580–6. doi: 10.1089/gtmb.2014.0102. PubMed DOI

Herreros-Villanueva M, Bujanda L, Billadeau DD, Zhang JS. Embryonic stem cell factors and pancreatic cancer. World J Gastroenterol. 2014;20(9):2247–54. doi: 10.3748/wjg.v20.i9.2247. PubMed DOI PMC